These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Afrin LB; Weinstock LB; Molderings GJ Int J Infect Dis; 2020 Nov; 100():327-332. PubMed ID: 32920235 [TBL] [Abstract][Full Text] [Related]
3. Mast Cell Activation Syndrome in COVID-19 and Female Reproductive Function: Theoretical Background vs. Accumulating Clinical Evidence. Szukiewicz D; Wojdasiewicz P; Watroba M; Szewczyk G J Immunol Res; 2022; 2022():9534163. PubMed ID: 35785029 [TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of Post-COVID syndromes: a new perspective. Batiha GE; Al-Kuraishy HM; Al-Gareeb AI; Welson NN Virol J; 2022 Oct; 19(1):158. PubMed ID: 36210445 [TBL] [Abstract][Full Text] [Related]
5. Mast cell activation syndrome and the link with long COVID. Arun S; Storan A; Myers B Br J Hosp Med (Lond); 2022 Jul; 83(7):1-10. PubMed ID: 35938771 [TBL] [Abstract][Full Text] [Related]
6. Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview. Matito A; Escribese MM; Longo N; Mayorga C; Luengo-Sánchez O; Pérez-Gordo M; Matheu V; Labrador-Horrillo M; Pascal M; Seoane-Reula ME; J Investig Allergol Clin Immunol; 2021 Dec; 31(6):461-470. PubMed ID: 33541851 [TBL] [Abstract][Full Text] [Related]
7. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. Gülen T; Akin C; Bonadonna P; Siebenhaar F; Broesby-Olsen S; Brockow K; Niedoszytko M; Nedoszytko B; Oude Elberink HNG; Butterfield JH; Sperr WR; Alvarez-Twose I; Horny HP; Sotlar K; Schwaab J; Jawhar M; Zanotti R; Nilsson G; Lyons JJ; Carter MC; George TI; Hermine O; Gotlib J; Orfao A; Triggiani M; Reiter A; Hartmann K; Castells M; Arock M; Schwartz LB; Metcalfe DD; Valent P J Allergy Clin Immunol Pract; 2021 Nov; 9(11):3918-3928. PubMed ID: 34166845 [TBL] [Abstract][Full Text] [Related]
8. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. Valent P; Akin C; Nedoszytko B; Bonadonna P; Hartmann K; Niedoszytko M; Brockow K; Siebenhaar F; Triggiani M; Arock M; Romantowski J; Górska A; Schwartz LB; Metcalfe DD Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261124 [TBL] [Abstract][Full Text] [Related]
9. Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research. Scheppke KA; Pepe PE; Jui J; Crowe RP; Scheppke EK; Klimas NG; Marty AM Am J Emerg Med; 2024 Jan; 75():122-127. PubMed ID: 37944296 [TBL] [Abstract][Full Text] [Related]
10. Long COVID symptoms in SARS-CoV-2-positive children aged 0-14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study. Kikkenborg Berg S; Palm P; Nygaard U; Bundgaard H; Petersen MNS; Rosenkilde S; Thorsted AB; Ersbøll AK; Thygesen LC; Nielsen SD; Vinggaard Christensen A Lancet Child Adolesc Health; 2022 Sep; 6(9):614-623. PubMed ID: 35752194 [TBL] [Abstract][Full Text] [Related]
11. Severe Fatigue in Long COVID: Web-Based Quantitative Follow-up Study in Members of Online Long COVID Support Groups. Van Herck M; Goërtz YMJ; Houben-Wilke S; Machado FVC; Meys R; Delbressine JM; Vaes AW; Burtin C; Posthuma R; Franssen FME; Hajian B; Vijlbrief H; Spies Y; van 't Hul AJ; Janssen DJA; Spruit MA J Med Internet Res; 2021 Sep; 23(9):e30274. PubMed ID: 34494964 [TBL] [Abstract][Full Text] [Related]
12. Examination of autoantibodies to type I interferon in patients suffering from long COVID. Hansen KS; Jørgensen SE; Skouboe MK; Agergaard J; Schiøttz-Christensen B; Vibholm LK; Tolstrup M; Østergaard L; Leth S; Mogensen TH J Med Virol; 2023 Sep; 95(9):e29089. PubMed ID: 37698062 [TBL] [Abstract][Full Text] [Related]
13. Long-Term Symptoms Among Adults Tested for SARS-CoV-2 - United States, January 2020-April 2021. Wanga V; Chevinsky JR; Dimitrov LV; Gerdes ME; Whitfield GP; Bonacci RA; Nji MAM; Hernandez-Romieu AC; Rogers-Brown JS; McLeod T; Rushmore J; Lutfy C; Bushman D; Koumans E; Saydah S; Goodman AB; Coleman King SM; Jackson BR; Cope JR MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(36):1235-1241. PubMed ID: 34499626 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of hydroxyurea in mast cell activation syndrome patients refractory to standard medical therapy: retrospective case series. Weinstock LB; Brook JB; Molderings GJ Naunyn Schmiedebergs Arch Pharmacol; 2022 Nov; 395(11):1441-1447. PubMed ID: 35982335 [TBL] [Abstract][Full Text] [Related]
17. Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. Theoharides TC; Cholevas C; Polyzoidis K; Politis A Biofactors; 2021 Mar; 47(2):232-241. PubMed ID: 33847020 [TBL] [Abstract][Full Text] [Related]
18. [Monitoring the development of post-COVID–19 syndrome]. Tamasi J; Kalabay L Orv Hetil; 2022 Feb; 163(9):335-342. PubMed ID: 35220274 [TBL] [Abstract][Full Text] [Related]
19. Connecting the Dots in Emerging Mast Cell Research: Do Factors Affecting Mast Cell Activation Provide a Missing Link between Adverse COVID-19 Outcomes and the Social Determinants of Health? da Silveira Gorman R; Syed IU Med Sci (Basel); 2022 May; 10(2):. PubMed ID: 35736349 [TBL] [Abstract][Full Text] [Related]
20. Orthostatic Symptoms and Reductions in Cerebral Blood Flow in Long-Haul COVID-19 Patients: Similarities with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Campen CLMCV; Rowe PC; Visser FC Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056336 [No Abstract] [Full Text] [Related] [Next] [New Search]